FDA Classifies Fibromyalgia Nerve Stimulator as Class II
Published Date: 5/29/2026
Rule
Summary
The FDA is officially classifying the transcutaneous electrical nerve stimulator for fibromyalgia as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get easier access to this innovative treatment by cutting down red tape. The new classification is effective May 29, 2026, and could speed up device availability without extra costs for makers or users.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Device moved to Class II (easier access)
The FDA officially classified the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms as a Class II (special controls) device effective May 29, 2026 (classification applicable May 18, 2022). FDA says this classification reduces regulatory burdens and can enhance patients' access to this treatment and could speed up device availability without extra costs for makers or users.
De Novo device can serve as 510(k) predicate
Because the device was classified via the De Novo process, it can serve as a predicate device for future devices, letting other sponsors use the less-burdensome 510(k) process instead of a De Novo request or premarket approval application.
Device is subject to 510(k) submission now
The document states that transcutaneous electrical nerve stimulators to treat fibromyalgia symptoms are subject to premarket notification under section 510(k) of the FD&C Act at this time (FDA has not determined the device type should be exempt under section 510(m)).
Special controls require safety testing and labeling
FDA established special controls that require non-clinical performance testing (electrical parameter characterization, electrode performance, impedance monitoring), biocompatibility for patient-contacting components, electrical/thermal/mechanical safety and electromagnetic compatibility testing, software verification/validation/hazard analysis, and specific labeling (treatment regimes, electrode shelf life/reuse, device technical summaries, and user instructions).
Device is prescription-only
FDA identifies the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms as a prescription device, meaning patients must receive it through a prescription rather than over-the-counter.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10734 — Content of Human Factors Information in Medical Device Marketing Submissions; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just released new guidance to help medical device makers include the right human factors info in their marketing submissions. This makes the review process faster and clearer for everyone involved. If you make or review medical devices, get ready to follow these updated steps starting now—saving time and possibly money!
2026-10674 — Advisory Committee; Psychopharmacologic Drugs Advisory Committee; Renewal
The FDA is renewing the Psychopharmacologic Drugs Advisory Committee for two more years, keeping it active until June 4, 2028. This committee helps make sure psychiatric drugs are safe and effective, affecting drug makers, doctors, and patients. No new costs or big changes, just a smooth continuation of expert advice to keep mental health treatments on track.
2026-10703 — Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application; Guidance for Industry; Availability
The FDA just released final guidance to help drug companies prove their generic drugs work just like the original ones by using bioequivalence studies. This affects anyone submitting or updating abbreviated new drug applications (ANDAs) and aims to make the approval process clearer and smoother. Companies should review these new rules now to avoid delays and extra costs when getting their generics to market.
2026-10614 — Color Additive Petition from Environmental Defense Fund, et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove three harmful solvents—ethylene dichloride, methylene chloride, and trichloroethylene—from color additive rules. This change affects companies using these solvents in color additives and aims to make products safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any final decisions.
2026-10615 — Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove four harmful solvents—benzene, ethylene dichloride, methylene chloride, and trichloroethylene—from food additive rules. This change affects food makers who use these solvents and aims to make our food safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any costly changes happen.
2026-10603 — Challenges and Solutions in Lot-Level Food Traceability; Public Meeting and Request for Comments
The FDA is hosting a virtual meeting on June 15, 2026, to talk about how to better track food by its lot number, making food safer and easier to trace. This affects food producers, sellers, and anyone involved in food safety, with a chance to suggest flexible ways to follow the rules. Comments on the ideas are open until July 15, 2026, so get involved and help shape the future of food tracking!
Previous / Next Documents
Previous: 2026-10621 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Suturing Device for Altering Gastric Anatomy for Weight Loss
The FDA is officially classifying the endoscopic suturing device for weight loss as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative tool faster and ensures it’s safe and effective. The new rules took effect on May 28, 2026, and could save time and money for makers and users alike.
Next: 2026-10709 — Bacillus Thuringiensis Cry1B.34.1, Bacillus Thuringiensis Cry1B.61.1 and Adiantum Trapeziforme var. Braziliense IPD083Cb Proteins; Pesticide Tolerances
The EPA just said it’s okay to have tiny amounts of three special proteins—Cry1B.34.1, Cry1B.61, and IPD083Cb—in all food and animal feed without setting strict limits. This helps farmers and food makers use these proteins safely in crops to protect plants from pests. The new rule kicks in on May 29, 2026, and anyone who wants to object has until July 28, 2026, to speak up.